sugammadex-teva sugammadex (as sodium) 200 mg/2 ml solution for injection vial
teva pharma australia pty ltd - sugammadex sodium, quantity: 217.6 mg (equivalent: sugammadex, qty 200 mg) - injection, solution - excipient ingredients: water for injections; sodium hydroxide; hydrochloric acid - reversal of neuromuscular blockade induced by rocuronium or vecuronium in patients 2 years of age and older.
sugammadex- sugammadex injection sugammadex- sugammadex injection, solution
camber pharmaceuticals, inc. - sugammadex sodium (unii: erj6x2mxv7) (sugammadex - unii:361lpm2t56) - sugammadex injection is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adults undergoing surgery. pediatric use information is approved for merck sharp & dohme corp., a subsidiary of merck & co. inc.’s bridion ® (sugammadex injection). however, due to merck sharp & dohme corp., a subsidiary of merck & co. inc.’s marketing exclusivity rights, this drug product is not labeled with that information. sugammadex is contraindicated in patients with known hypersensitivity to sugammadex or any of its components. hypersensitivity reactions that occurred varied from isolated skin reactions to serious systemic reactions (i.e., anaphylaxis, anaphylactic shock) and have occurred in patients with no prior exposure to sugammadex [see warnings and precautions (5.1), adverse reactions (6)]. risk summary there are no clinical trial data on sugammadex use in pregnant women to inform any drug-associated risks. the available data from
sugammadex piramal
piramal critical care b.v. - sugammadex sodium - neuromuscular blockade - sugammadex - reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults.
sugammadex-teva sugammadex (as sodium) 500 mg/5 ml solution for injection vial
teva pharma australia pty ltd - sugammadex sodium, quantity: 544 mg (equivalent: sugammadex, qty 500 mg) - injection, solution - excipient ingredients: water for injections; hydrochloric acid; sodium hydroxide - reversal of neuromuscular blockade induced by rocuronium or vecuronium in patients 2 years of age and older.
sugammadex mylan
mylan ireland limited - sugammadex sodium - neuromuscular blockade - all other therapeutic products - reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults.for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.
sugammadex fresenius kabi
fresenius kabi deutschland gmbh - sugammadex sodium - neuromuscular blockade - all other therapeutic products - reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults.for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.
sugammadex amomed
aop orphan pharmaceuticals gmbh - sugammadex sodium - neuromuscular blockade - all other therapeutic products - reversal of neuromuscular blockade induced by rocuronium or vecuronium.for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.
sugammadex adroiq
extrovis eu ltd. - sugammadex sodium - neuromuscular blockade - all other therapeutic products - reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults.for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.
sugammadex 100 mg/ml solution for injection
baxter holding b.v. - sugammadex sodium - solution for injection - sugammadex
sugammadex rowex 100 mg/ml solution for injection
rowex ltd - sugammadex sodium - solution for injection - 100 milligram(s)/millilitre - sugammadex